Literature DB >> 6210303

Phenotypic markers and functional characteristics of T lymphocyte clones from cerebrospinal fluid in multiple sclerosis.

B Fleischer, P Marquardt, S Poser, H W Kreth.   

Abstract

We have recently developed a technique for direct expansion of human T lymphocyte clones from cerebrospinal fluid (CSF) of patients with acute infections of the central nervous system (CNS). In the present study, T lymphocyte clones were established directly from the CSF of 4 patients with multiple sclerosis by limiting dilution in the presence of T cell growth factor and irradiated feeder cells. In 3 patients the CSF was obtained during an exacerbation of their disease. Cloning efficiencies ranged between 4 and 6%. About 40 clones per patient were available for surface marker analysis and functional studies. Typing of the clones for membrane antigens revealed the following results: 75-100% had the OKT4+8- and 0-25% the OKT4-8+ phenotype. Only one clone expressed both surface markers. When tested for PHA-dependent cytotoxicity, all OKT8+ clones and about 50% of the OKT4+ clones were found to express cytotoxic activity. Studies on the proliferative response showed that all OKT4+ and the majority of OKT8+ clones were capable of TCGF-independent, mitogen-induced proliferation. Screening of the clones for specific reactivity against a panel of antigens including measles virus, mumps virus, Epstein-Barr virus and myelin basic protein (MBP) did not reveal significant specific reactivity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6210303     DOI: 10.1016/s0165-5728(84)80015-6

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

Review 1.  T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  F T Rotteveel; C J Lucas
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

2.  Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis.

Authors:  M Matsui; H Fukuyama; I Akiguchi; M Kameyama
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

3.  Tumour necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis.

Authors:  R Benvenuto; M Paroli; C Buttinelli; A Franco; V Barnaba; C Fieschi; F Balsano
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

4.  Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma.

Authors:  T Olsson; W W Zhi; B Höjeberg; V Kostulas; Y P Jiang; G Anderson; H P Ekre; H Link
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

5.  Analysis of T-cell cultures and clones from a patient with classic rheumatoid arthritis--evidence for the existence of autoreactive T-cell clones in blood and synovial fluid.

Authors:  M Schlesier; C Ramb-Lindhauer; M Gärtner; H H Peter
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

6.  Analysis of T cell receptor beta and gamma genes from peripheral blood, regional lymph node and tumor-infiltrating lymphocyte clones from melanoma patients.

Authors:  M R Albertini; J A Nicklas; B F Chastenay; T C Hunter; R J Albertini; S S Clark; J A Hank; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Characteristics of T-lymphocytes infiltrating human B-cell lymphomas.

Authors:  P Marquardt; H K Müller-Hermelink
Journal:  Environ Health Perspect       Date:  1990-08       Impact factor: 9.031

8.  Virus-specific and autoreactive T cell lines isolated from cerebrospinal fluid of a patient with chronic rubella panencephalitis.

Authors:  R Martin; P Marquardt; S O'Shea; M Borkenstein; H W Kreth
Journal:  J Neuroimmunol       Date:  1989-06       Impact factor: 3.478

9.  Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  D A Hafler; A D Duby; S J Lee; D Benjamin; J G Seidman; H L Weiner
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.